HLYK on OTC
HealthLynked Corp
American Offices and Clinics of Doctors of Medicine services company. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Basel Medical Group Ltd, Cardiff Lexington Corp or Concord Medical Services Holdings Ltd, or pick any stock.
- TickerHLYK on OTC1
- IndustryServices-Offices & Clinics of Doctors of Medicine1
- HeadquartersNaples, Florida1
- Incorporated inNV2
- Business address1265 Creekside Parkway, Suite 302, Naples, Fl 341082
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
AI-enabled features), on-demand telemedicine services, and concierge support, delivering a technology-enabled patient experience.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Patent Service Revenue Net brought in 48% of the revenue HealthLynked Corp broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Patent Service Revenue Net | $2.9M | $2.0M |
| Patient Service Revenue Net | $2.9M | $2.0M |
| Product And Other Revenue | $103.8K | $40.1K |
| Product Revenue | $103.8K | $40.1K |
| Subscription And Event Revenue | $32.4K | $22.6K |
| Subscription Revenue | $32.4K | $22.6K |
Business segments
Health Services brought in 97% of the revenue HealthLynked Corp broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Health Services | $2.9M | $2.0M |
| Medical Distribution | $103.8K | $40.1K |
| Digital Healthcare | $32.4K | $22.6K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin99¢$2.0M
- Other costs1¢$29.8K
Out of $2.1M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $2.1M | $3.0M |
| Practice salaries and benefits | $1.0M | $2.0M |
| Other practice operating expenses | $973.0K | $1.6M |
| Cost of product revenue | $51.6K | $96.2K |
| Selling, general and administrative expenses | $2.0M | $3.0M |
| Depreciation and amortization | $101.9K | $282.9K |
| Impairment loss | $716.0K | |
| Total Operating Expenses and Costs | $4.2M | $7.7M |
| Loss from operations | -$2.1M | -$4.7M |
| Gain (loss) on extinguishment of debt | $318.0K | -$179.0K |
| Gain (loss) on change in fair value of debt | -$618.2K | $84.1K |
| Gain on sale of assets | $168.7K | |
| Gain on change in fair value of derivative financial instruments | $8.6K | |
| Amortization of original issue discounts on notes payable | -$828.0K | -$1.3M |
| Gain from realization of contingent sale consideration receivable | $125.4K | |
| Interest expense and other | -$216.1K | -$168.1K |
| Total other income (expenses) | -$1.2M | -$1.5M |
| Loss before provision for income taxes | -$3.3M | -$6.1M |
| Net loss | -$3.3M | -$6.1M |
| Basic (in Dollars per share) | -$1.16 | -$2.18 |
| Fully diluted (in Dollars per share) | -$1.16 | -$2.18 |
| Basic (in Shares) | 2.8M shares | 2.8M shares |
| Fully diluted (in Shares) | 2.8M shares | 2.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $37.1K | $76.2K | $247.2K |
| Inventory, net | $18.0K | $44.7K | |
| Prepaid expenses and other current assets | $32.9K | $56.7K | |
| Contingent sale consideration receivable, current portion | $1.5M | $1.5M | |
| Total Current Assets | $1.6M | $1.6M | |
| Property and equipment, net of accumulated depreciation of $728,710 and $634,839 as of December 31, 2025 and 2024, respectively | $74.7K | $176.6K | |
| Right of use lease assets | $76.1K | $361.1K | |
| Deposits, long term portion | $44.1K | ||
| Total Assets | $1.7M | $2.2M | |
| Accounts payable, accrued expenses and other current liabilities | $821.5K | $765.3K | |
| Contract liabilities | $25.9K | $232.5K | |
| Lease liability, current portion | $75.2K | $208.5K | |
| Derivative financial instruments | $23.8K | ||
| Notes payable, current portion, net of unamortized original issue discount of $109,027 and $27,414 as of December 31, 2025 and 2024, respectively | $389.7K | $127.1K | |
| Indemnification liability | $144.0K | $144.0K | |
| Total Current Liabilities | $7.0M | $4.7M | |
| Lease liability, long term portion | $922 | $153.6K | |
| Government and other notes payable, long term portion | $450.0K | $508.6K | |
| Total Liabilities | $7.5M | $5.4M | |
| Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 2,881,104 and 2,821,877 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $288 | $282 | |
| Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $2.8K | $2.8K | |
| Common stock issuable, $0.0001 par value; 22,052 and 30,632 as of December 31, 2025 and 2024, respectively | $61.3K | $161.6K | |
| Additional paid-in capital | $44.7M | $44.9M | |
| Accumulated deficit | -$50.5M | -$48.2M | |
| Total Shareholders Deficit | -$5.8M | -$3.1M | $804.7K |
| Total Liabilities and Shareholders Deficit | $1.7M | $2.2M | |
| Property and equipment, net of accumulated depreciation | $728.7K | $634.8K | |
| Net of unamortized original issue discount | $109.0K | $27.4K | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares issued (in Shares) | 2.9M shares | 2.9M shares | |
| Common stock, shares outstanding (in Shares) | 2.8M shares | 2.8M shares | |
| Common stock issuable, par value (in Dollars per share) | $0 | $0 | |
| Common stock issuable, shares (in Shares) | 22.1K shares | 30.6K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $37.1K | $76.2K | $247.2K |
| Inventory, net | $18.0K | $44.7K | |
| Prepaid expenses and other current assets | $32.9K | $56.7K | |
| Contingent sale consideration receivable, current portion | $1.5M | $1.5M | |
| Total Current Assets | $1.6M | $1.6M | |
| Property and equipment, net of accumulated depreciation of $728,710 and $634,839 as of December 31, 2025 and 2024, respectively | $74.7K | $176.6K | |
| Right of use lease assets | $76.1K | $361.1K | |
| Deposits, long term portion | $44.1K | ||
| Total Assets | $1.7M | $2.2M | |
| Accounts payable, accrued expenses and other current liabilities | $821.5K | $765.3K | |
| Contract liabilities | $25.9K | $232.5K | |
| Lease liability, current portion | $75.2K | $208.5K | |
| Derivative financial instruments | $23.8K | ||
| Notes payable, current portion, net of unamortized original issue discount of $109,027 and $27,414 as of December 31, 2025 and 2024, respectively | $389.7K | $127.1K | |
| Indemnification liability | $144.0K | $144.0K | |
| Total Current Liabilities | $7.0M | $4.7M | |
| Lease liability, long term portion | $922 | $153.6K | |
| Government and other notes payable, long term portion | $450.0K | $508.6K | |
| Total Liabilities | $7.5M | $5.4M | |
| Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 2,881,104 and 2,821,877 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $288 | $282 | |
| Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $2.8K | $2.8K | |
| Common stock issuable, $0.0001 par value; 22,052 and 30,632 as of December 31, 2025 and 2024, respectively | $61.3K | $161.6K | |
| Additional paid-in capital | $44.7M | $44.9M | |
| Accumulated deficit | -$50.5M | -$48.2M | |
| Total Shareholders Deficit | -$5.8M | -$3.1M | $804.7K |
| Total Liabilities and Shareholders Deficit | $1.7M | $2.2M | |
| Property and equipment, net of accumulated depreciation | $728.7K | $634.8K | |
| Net of unamortized original issue discount | $109.0K | $27.4K | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares issued (in Shares) | 2.9M shares | 2.9M shares | |
| Common stock, shares outstanding (in Shares) | 2.8M shares | 2.8M shares | |
| Common stock issuable, par value (in Dollars per share) | $0 | $0 | |
| Common stock issuable, shares (in Shares) | 22.1K shares | 30.6K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$3.3M | -$6.1M |
| Depreciation and amortization | $101.9K | $282.9K |
| Impairment loss | $716.0K | |
| Stock based compensation, including amortization of deferred equity compensation | $158.6K | $210.3K |
| Gain on change in fair value of derivative financial instruments | -$8.6K | |
| Amortization of debt discount | $828.0K | $1.3M |
| (Gain) loss on extinguishment of debt | -$318.0K | $179.0K |
| Change in fair value of debt | $618.2K | -$84.1K |
| Gain on sale of assets | -$168.7K | |
| Gain from realization of contingent sale consideration receivable | -$125.4K | |
| Other non-cash adjustments | -$1.7K | |
| Accounts receivable | $20.9K | |
| Inventory | $26.7K | $88.5K |
| Contract assets | $20.1K | -$14.9K |
| Prepaid expenses and other current assets | $47.9K | $19.3K |
| Right of use lease assets | $183.2K | $309.2K |
| Accounts payable and accrued expenses | $424.4K | $70.9K |
| Lease liability | -$184.3K | -$310.6K |
| Contract liabilities | -$162.9K | -$39.2K |
| Net cash used in operating activities | -$1.7M | -$3.5M |
| Proceeds from sale of ACO Business | $425.0K | |
| Proceeds from sale of assets of BTG business | $125.0K | |
| Acquisition of property and equipment | -$2.6K | |
| Net cash used in investing activities | $125.0K | $422.4K |
| Proceeds from sale of common stock | $30.0K | $405.0K |
| Proceeds from related party notes payable and advances | $1.6M | $3.3M |
| Proceeds from third party notes payable | $630.0K | $335.0K |
| Repayment of related party notes payable and advances | -$136.0K | -$167.6K |
| Repayment of third party notes payable | -$584.1K | -$941.7K |
| Net cash provided by financing activities | $1.5M | $2.9M |
| Net decrease in cash | -$39.1K | -$171.0K |
| Cash paid during the period for interest | $15.4K | $26.3K |
| Recognition of operating lease: right of use asset and lease liability | $30.0K | $177.8K |
| Extinguishment of operating lease: right of use asset and lease liability | -$131.8K | -$444.4K |
| Fair value of options issued in satisfaction of common stock issuable | $283.9K | |
| Fair value of warrants allocated to proceeds of related party notes payable | $758.5K | |
| Fair value of derivative financial instruments allocated to proceeds of third party notes payable | $90.3K | |
| Fair value of beneficial conversion feature allocated to proceeds of related party notes payable | $100.5K | $785.0K |
| Original issue discounts allocated to proceeds of notes payable | $239.7K | $164.0K |
| Reclassification of historical amounts recognized for beneficial conversion features | $10.2K | |
| Fair value of warrants issued to extend related party debt | $73.6K | $38.6K |
| Principal amount of convertible notes payable to related party refinanced | $3.9M | $866.5K |
| Incremental fair value of convertible note payable to related party resulting from refinancing | $48.1K | |
| Forgiveness of related party debt | $245.0K | |
| Expenses paid by related party | $24.8K | |
| Fair value of shares issued for equity issuance costs | $9.0K | $35.1K |
| Accrued interest included in fair value of note payable | $290.5K | $17.6K |
| Accounts payable included in principal balance of notes payable to related party | $27.7K | |
| Fair value of stock options issued to reduce accounts payable | $38.3K | |
| Impact on par value of common stock from reverse stock split | $28.2K |
No quarter-by-quarter statement was filed.
Leadership
Who has led HealthLynked Corp, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerMichael T. Dent Feb 16, 2018 to now12
- Chief financial officerJeremy Daniel Jan 15, 2025 to Jan 15, 202513
- Chief financial officerDavid Rosal Mar 27, 2024 to Jun 24, 202414
- Chief operating officerWilliam Crupi Jun 27, 2024 to Jun 27, 202415
Board members and other officers (6)
- Board memberPaul Hobaica Apr 12, 2023 to Oct 6, 202316
- Board memberRobert P. Mino Mar 3, 2020 to Nov 24, 202117
- Board memberRobert P. Gasparini Mar 13, 2020 to Oct 6, 202318
- Board memberDaniel L. Hall Nov 12, 2020 to Oct 6, 202319
- Board memberHeather Monahan Nov 12, 2020 to Oct 6, 202320
- Board memberMichael T. Dent Feb 16, 2018 to now12
Timeline
- Feb 16, 2018New chief executive Michael T. Dent becomes CEO12
Filings
99 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 21 major events, 41 insider forms, 16 other. The latest 20:
- Aug 14, 202610-Q QUARTERLY REPORT EDGAR
- Jul 24, 20264 EDGAR
- Jul 16, 20268-K CURRENT REPORT EDGAR
- May 29, 2026S-1/A AMENDMENT NO. 2 TO FORM S-1 EDGAR
- May 15, 202610-Q QUARTERLY REPORT EDGAR
- Apr 30, 2026S-1/A AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Mar 31, 202610-K ANNUAL REPORT EDGAR
- Feb 10, 2026S-1 REGISTRATION STATEMENT EDGAR
- Feb 6, 20268-K CURRENT REPORT EDGAR
- Jan 9, 2026DRS EDGAR
- Dec 12, 20258-K CURRENT REPORT EDGAR
- Nov 19, 202510-Q QUARTERLY REPORT EDGAR
- Nov 17, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- Sep 5, 20258-K CURRENT REPORT EDGAR
- Aug 14, 202510-Q QUARTERLY REPORT EDGAR
- May 15, 202510-Q QUARTERLY REPORT EDGAR
- Apr 30, 20251-A EDGAR
- Apr 18, 20254 EDGAR
- Apr 10, 20254 EDGAR
- Mar 31, 20254 EDGAR
The 99 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 24, 2024 | Rosal DavidChief Financial Officer | Buy | 28,333 | $0.08 | $2.3K | Form 4 |
| Jun 20, 2024 | Rosal DavidChief Financial Officer | Buy | 33,667 | $0.08 | $2.7K | Form 4 |
From Forms 4 filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Ancora Advisors LLC | 74 | $222 | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARDavid Rosal, Chief financial officer
- 15
- 16SEC EDGARPaul Hobaica, Board member
- 17SEC EDGARRobert P. Mino, Board member
- 18SEC EDGARRobert P. Gasparini, Board member
- 19SEC EDGARDaniel L. Hall, Board member
- 20SEC EDGARHeather Monahan, Board member